Amryt Pharma Plc’s Product AP101 Gets FDA’s Fast Track Designation

  • Oct 01, 2019 BST
  • Team Kalkine
  • Amryt Pharma Plc’s (AMYT) product AP101 (Oleogel-S10) investigation has been designated Fast Track development program from the US Food and Drug Administration.
  • AP101 Epidermolysis Bullosa has been recognised by Food and Drug Administration (FDA) as a serious disease with no FDA-approved treatments for this condition.
  • The company has generated preliminary clinical data from an ongoing Phase 3 trial, which as per FDA supports the continued study.
  • On 1st October 2019, at the time of writing, GMT 08:12 AM, AMYT shares were trading at GBX 134.00, up by 3.00 points or 2.29% against the previous day closing price.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK